Dendron Stabilizer for Bio-therapeutics at 55°C
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stabilizing bio-therapeutics, such as proteins, require refrigeration to prevent thermal degradation, which is costly and impractical for resource-constrained regions, especially in Sub-Saharan Africa where high temperatures render life-saving drugs ineffective.
Innovation Solution
A dendron-based formulation that includes a dendron of specific structure, monoclonal antibodies, a buffer solution, and a salt, which stabilizes bio-therapeutics at temperatures up to 55°C, preventing degradation and maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If refrigeration is used to stabilize bio-therapeutics, then thermal degradation is prevented, but storage cost and operational complexity increase
Solution Approach 1:
The patent changes the chemical parameters of the formulation by incorporating specific stabilizing agents (sugars, amino acids, peptides, proteins, or their combinations) that enable the bio-therapeutics to maintain stability at higher temperatures (up to 55°C) without requiring refrigeration. This parameter change in the formulation composition directly resolves the contradiction by eliminating the need for complex refrigeration systems while preserving therapeutic stability.
2Stability of the object's composition
If refrigeration is used to stabilize bio-therapeutics, then thermal degradation is prevented, but implementation difficulty in resource-constrained regions increases
Solution Approach 1:
By modifying the formulation to include thermoprotective agents that raise the stable storage temperature range, the patent makes the bio-therapeutics suitable for storage in hot and humid conditions without refrigeration. This enables distribution to resource-constrained regions where refrigeration infrastructure is unavailable, directly improving ease of operation and accessibility.
3Ease of manufacture
If high temperature storage is attempted without stabilization, then refrigeration cost is reduced, but therapeutic efficacy is lost due to degradation
Solution Approach 1:
The patent incorporates specific stabilizing agents (sugars, amino acids, peptides, proteins) in defined concentrations that chemically protect the bio-therapeutics from thermal degradation. These agents maintain the structural integrity and biological activity of the therapeutics even at elevated temperatures (up to 55°C), thereby enabling cost-effective storage without refrigeration while preserving therapeutic efficacy.
4Stability of the object's composition
If existing stabilization methods are used, then some protection is achieved, but stability at temperatures above 25°C is insufficient
Solution Approach 1:
The patent employs composite stabilization strategies by combining multiple types of stabilizing agents (sugars, amino acids, peptides, and/or proteins) in specific formulations. This composite approach creates synergistic effects that significantly elevate the maximum stable storage temperature from typical refrigerated conditions (2-8°C) to ambient and even elevated temperatures (up to 55°C), resolving the temperature limitation of existing methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively stabilizes bio-therapeutics at high temperatures, ensuring their integrity and functionality for extended periods without significant degradation, thus addressing the challenge of thermal instability in existing methods.
Implementation Method 1
the dendron stabilizes the bio-therapeutic in the formulation at a temperature of up to 55 °C
Implementation Method 2
A dendron-based formulation that includes a dendron of specific structure, monoclonal antibodies, a buffer solution, and a salt, which stabilizes bio-therapeutics at temperatures up to 55°C, preventing degradation
Data Source
Figure 1A~1C
Figure 2A~2D
Figure 3A~3D
AI summary
The present disclosure relates to a formulation comprising: a) a dendron of Formula I; b) at least one bio-therapeutic; c) at least one buffer; and d) at least one salt, wherein the bio-therapeutic to dendron molar ratio is in the range of 1:0.5-1:3. The dendron stabilizes the bio-therapeutic in the formulation at a temperature of up to 55 °C.